Show simple item record

dc.contributor.authorHorwich, Alan
dc.contributor.authorMacLennan, Steven
dc.contributor.authorEAU and ESMO Guidelines Committees
dc.date.accessioned2020-11-19T00:04:45Z
dc.date.available2020-11-19T00:04:45Z
dc.date.issued2019-11
dc.identifier.citationHorwich , A , MacLennan , S & EAU and ESMO Guidelines Committees 2019 , ' EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort : under the auspices of the EAU and ESMO Guidelines Committees ' , Annals of Oncology , vol. 30 , no. 11 , pp. 1697–1727 . https://doi.org/10.1093/annonc/mdz296en
dc.identifier.issn0923-7534
dc.identifier.otherPURE: 146863386
dc.identifier.otherPURE UUID: 802d9301-e68f-449a-83a2-81e6699c967d
dc.identifier.otherPubMed: 31740927
dc.identifier.otherWOS: 000507594800008
dc.identifier.otherScopus: 85077175940
dc.identifier.otherORCID: /0000-0002-2691-8421/work/79061765
dc.identifier.urihttps://hdl.handle.net/2164/15378
dc.descriptionACKNOWLEDGEMENTS The authors would like to thank Peter E Clark from Atrium Health, Levine Cancer Institute, Charlotte, NC, USA, for his contribution to the Delphi survey. Angela Corstorphine of Kstorfin Medical Communications Ltd provided medical writing support with the preparation of this manuscript; this support was funded jointly by EAU and ESMO. FUNDING All costs relating to the consensus conference were covered jointly by the European Association of Urology and the European Society for Medical Oncology. There was no external funding of the event or manuscript production.en
dc.format.extent31
dc.language.isoeng
dc.relation.ispartofAnnals of Oncologyen
dc.rightsThis is a pre-copyedited, author-produced version of an article accepted for publication in Annals of Oncology following peer review. The version of record EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees, Annals of Oncology, , mdz296, is available online at: https://academic.oup.com/annonc/article/30/11/1697/5629133en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectbladder canceren
dc.subjectconsensusen
dc.subjectDelphien
dc.subjectdiagnosisen
dc.subjecttreatmenten
dc.subjectfollow-upen
dc.subjectPROGNOSTIC-FACTORSen
dc.subjectTUMOR RESPONSEen
dc.subjectMETASTATIC UROTHELIAL CARCINOMAen
dc.subjectFOLLOW-UPen
dc.subjectSINGLE-ARMen
dc.subjectLONG-TERM-SURVIVALen
dc.subjectLYMPHOCYTE RATIOen
dc.subjectCISPLATIN-INELIGIBLE PATIENTSen
dc.subjectTRANSITIONAL-CELL CARCINOMAen
dc.subjectRADICAL CYSTECTOMYen
dc.subjectR Medicine (General)en
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subject.lccR1en
dc.subject.lccRC0254en
dc.titleEAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort : under the auspices of the EAU and ESMO Guidelines Committeesen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Academic Urology Uniten
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPostprinten
dc.identifier.doihttps://doi.org/10.1093/annonc/mdz296
dc.identifier.vol30en
dc.identifier.iss11en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record